Bullish Case: CL just reported Q3 earnings (Oct 30) with the stock at $97.43 — up 10.4% in 60 days and 5.7% in a week — on momentum from 140bps gross-margin expansion and 27.9% FCF growth. Helium's density peaks near $94–95 with heavy mass at $100–105, call volume runs 64% above puts, and bullish risk is 30% higher than bearish. The front IV spike (58.6% → 16.9% by Nov 14) should decay now that earnings have passed, favoring a grind toward $98–102.

Bearish Case: The term structure is backwardated (front ~37.9% vs ~23.5% nine-months out), Helium's 11/06 options show 58.6% IV at the front with deep-put wings (89-strike puts at 58.6% IV) pricing a fat downside tail. North America organic sales fell 3.0%, payout ratios near 84% limit buybacks, 21x forward earnings with 2.3% yield competes against a 5.24% 10-year Treasury, and the 0.1 Helium-forecast correlation makes the bullish AI tilt unreliable.

Potential Outcomes:

1. ~35%: Post-earnings drift higher, $98–103 by mid-December — falsifiable if CL closes below $95 for 5 sessions while front IV collapses below 18%.
2. ~30%: Range chop $94–98 as event IV decays — falsifiable if price exits the band with stable later-tenor IV (~23%).
3. ~20%: Giveback −4–8% to $89–93 as the 10.4% 60-day rally mean-reverts and Treasury yields near 5.24% siphon staples demand — falsifiable if put skew richens with CL under $93.
4. ~10%: Vol+price joint drop >−8% (below $88) on macro/consumer shock — falsifiable if front IV spikes >35%.
5. ~5%: Breakout >$105 on guidance raise or P&G-restructuring-share-gain narrative (Pakistan acquisition signals in-market consolidation) — falsifiable by no catalyst through Q4.

November 03, 2026